KNSA Q3 2018 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$24M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$347M

Total Liabilities

$28M

Stockholders' Equity

$319M

Cash & Equivalents

$338M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$16M	-61.0%
Net Income	-$24M	-$16M	-52.3%